Advertisements
Feeds:
Posts
Comments

Search Results for 'Pfizer'


Originally posted on New Drug Approvals:
? Inotuzumab ozogamicin RN: 635715-01-4 UNII: P93RUU11P7 Pfizer Inc., Oncology Institute Of Southern Switzerland  INNOVATOR http://chem.sis.nlm.nih.gov/chemidplus/rn/635715-01-4 MF 1680.6764 Oncological Treatment FDA grants breakthrough status for Pfizer’s leukaemia drug inotuzumab ozogamicin The US Food and Drug Administration (FDA) has granted breakthrough therapy designation for Pfizer’s investigational antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat…

Read Full Post »


Merck and Pfizer Announces Global Strategic Alliance on Anti-PD-L1 to Accelerate Presence in Immuno-Oncology Reporter: Aviva Lev-Ari, PhD, RN   Merck KGaA, Darmstadt, Germany, and Pfizer will jointly develop and commercialize Merck KGaA, Darmstadt, Germany,’s anti-PD-L1 Joint investment and combined strengths and capabilities will further maximize potential of Merck KGaA, Darmstadt, Germany,’s asset in the […]

Read Full Post »


Pfizer Cambridge Collaborative Innovation Events: ‘The Role of Innovation Districts in Metropolitan Areas to Drive the Global an | Basecamp Business. Reporter: Stephen J. Williams, Ph.D. Monday, September 8 2014 5:30pm – 7:00pm Other Time Presented by: Pfizer Cambridge/Boston Site Head       Event Details:Date/Time: Monday, September 8, 2014, 5:30-7PM EDTVenue: Pfizer Cambridge Seminar […]

Read Full Post »


Pfizer Abandons Bid for AstraZeneca Regardless of Valuation of its Future Financials: The Destiny of Drug R&D Pipelines – The Case of AstraZeneca Reporter: Aviva Lev-Ari, PhD, RN UPDATED on 9/3/2014 ‘Back to normal’ for AstraZeneca CEO, despite Pfizer rumors BY BEN HIRSCHLER BARCELONA Tue Sep 2, 2014 8:59am EDT   (Reuters) – Though speculation is rife […]

Read Full Post »


AstraZeneca Makes Case Against the Friendly Pfizer’s Bid Reporter: Aviva Lev-Ari, PhD, RN US drug giant Pfizer has said commitments to preserve UK science jobs – if it wins a $106bn (£63bn) takeover of AstraZeneca – are legally binding. Pfizer has given a five-year promise to complete an AstraZeneca research centre in Cambridge, keep a […]

Read Full Post »


Reporter: Aviva Lev-Ari, PhD, RN Pfizer Inc. (PFE) Will Buy NextWave Pharmaceuticals for Up to $680 Million 10/22/2012 8:03:33 AM Pfizer Inc. | Jobs at Pfizer Inc. NEW YORK–(BUSINESS WIRE)–Pfizer Inc. (NYSE: PFE) today announced its intention to acquire NextWave Pharmaceuticals, a privately held, specialty pharmaceutical company focused on the development and commercialization of unique products for the treatment of […]

Read Full Post »


Curator: Aviva Lev-Ari, PhD, RN Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/  

Read Full Post »


Curator: Aviva Lev-Ari, PhD, RN Sunitinib brings Adult acute lymphoblastic leukemia (ALL) to Remission – RNA Sequencing – FLT3 Receptor Blockade https://pharmaceuticalintelligence.com/2012/07/09/sunitinib-brings-adult-all-to-remission-rna-sequencing/  

Read Full Post »


15th Annual Personalized Medicine Conference at Harvard Medical School – THE PARADIGM EVOLVES, November 13 – 14, 2019 • Harvard Medical School, Boston, MA   The 15th Annual Personalized Medicine Conference at Harvard Medical School will explore the science, business, and policy issues facing personalized medicine as scientists refine their understanding of how groundbreaking molecular diagnostics augmented […]

Read Full Post »


Laboratory for Genomics Research (LGR) to be established by GSK ($67M investment in 5 years) at UC, Berkeley/UCSF to be lead by Prof. Jennifer Doudna focusing on immunology, oncology, and neuroscience disease-causing gene mutations and development of new technologies using CRISPR to accelerate new drug discovery   Reporter: Aviva Lev-Ari, PhD, RN   GlaxoSmithKline, UC’s […]

Read Full Post »

« Prev - Next »